The main findings of the present study are as follows: Firstly, metformin improved the impaired lipid metabolism in chronic AF, as manifested by the increased expression of FAT, CPT-1, VLCSD and decreased lipid accumulation in the MET+AF group compared with AF group. The gene discussed is CD36; the disease is atrial fibrillation.